Squamous cell carcinoma antigen in cervical cancer and beyond

Kim, Byoung-Gie

doi:10.3802/jgo.2013.24.4.291

Cited by 15 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second part of our work, we examined the relationship between the SCC-Ag values and clinicopathologic features. Not surprisingly, the pretreatment SCC-Ag level was related to tumor aggressiveness as indicated by advanced stage, deep stromal invasion and lymph node metastasis, which was consistent with previous works [5,19]. Most published studies focused on the clinical value of one time-point of SCC-Ag and both the pretreatment level [10-12, 14, 15, 20, 22, 23], and posttreatment level [7, 8, 13-16, 18, 24].…”

Section: Discussionsupporting

confidence: 91%

“…The role of serum SCC-Ag in squamous cervical cancer has been extensively evaluated in previous works [4,7,8,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24], and several reviews and metaanalyses have been published in the literature [5,[25][26][27]. Most studies were of retrospective design and only detected SCC-Ag at one time-point.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Sun

Kang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: To study the kinetic profile and clinicopathological implications of squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients who underwent surgery by a self-developed SCC-Ag single molecule assay (Simoa) prototype immunoassay. Methods: Participants were prospectively enrolled between 04/2016 and 06/2017. Consecutive serum samples were collected at five points: day 0 (the day before surgery), postoperative day 4, weeks 2-4, months 2-4 and months 5-7. In total, 92 patients and 352 samples were included. The kinetic change in SCC-Ag levels and their associations with clinicopathological characteristics were studied. Results: Simoa SCC-Ag was validated by comparison with the Architect assay. SCC-Ag levels measured by the Simoa assay were highly correlated with the Architect assay's levels (Pearson's correlation coefficient = 0.979, Passing-Bablok regression slope 0.894 (0.847 to 0.949), intercept − 0.009 (− 0.047 to 0.027)). The median values for each time-point detected by the Simoa assay were 2.49, 0.66, 0.61, 0.72, and 0.71 ng/mL, respectively. The SCC-Ag levels decreased dramatically after surgery and then stabilized and fluctuated to some extent within 6 months. Patients with certain risk factors had significantly higher SCC-Ag values than their negative counterparts before surgery and at earlier time points after surgery, while no difference existed at the end of observation. Furthermore, although patients with positive lymph nodes had sustained higher SCC-Ag levels compared to those with negative lymph nodes, similar kinetic patterns of SCC-Ag levels were observed after surgery. Patients who received postoperative treatment had significantly higher SCC-Ag values than those with surgery only at diagnosis, while no difference existed after treatment. Conclusions: The Simoa SCC-Ag prototype was established for clinical settings. The SCC-Ag levels were higher in patients with risk factors, whereas the kinetic trend of SCC-Ag might be mainly affected by postoperative adjuvant therapy. These data indicate that the SCC-Ag level might be a good predictor for the status of cervical cancer, including disease aggressiveness and treatment response.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Sun

Kang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Squamous cell carcinoma antigen (SCCAg) is the serum tumor marker most commonly used for clinical monitoring of cervical squamous cell cancer(Kim 2013 ). Elevated pre-treatment SCCAg levels correlate with LNM and a poor prognosis in cervical squamous cell cancer (van de Lande et al 2009 ; Kawaguchi et al 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Can pelvic lymphadenectomy be omitted in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer?

et al. 2016

View full text Add to dashboard Cite

PurposeThis study aimed to identify the surgical-pathologic risk factors of lymph node metastasis (LNM) in patients with early stage squamous cell cervical cancer and to evaluate the potential efficacy of omitting pelvic lymphadenectomy.MethodsA total of 276 patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer receiving primary radical hysterectomy with pelvic lymphadenectomy were included in this study.ResultsThe incidences of LNM in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer were 0 % (0/8), 17.4 % (36/207), and 29.5 % (18/61), respectively. The most common location of LNM was the obturator lymph node. Human papilloma virus 16 subtype was the most common infection in early stage squamous cell cervical cancer. Univariate analysis revealed that squamous cell carcinoma antigen (SCCAg) greater than 1.5 μg/L (p < 0.001), tumor size greater than 2 cm (p < 0.001), tumor size greater than 3 cm (p < 0.001), depth of stromal invasion (p < 0.001) and lymphovascular invasion (p < 0.001) were associated with LNM. Logistic regression analysis revealed that depth of stromal invasion {model 1 [p = 0.006; odds ratio (OR) 2.161; 95 % confidence interval (CI) 1.251–3.734], model 2 [p = 0.002; OR 2.344; 95 % CI 1.337–3.989]}, lymphovascular invasion [model 1 (p = 0.004; OR 2.967; 95 % CI 1.411–6.237), model 2 (p = 0.004; OR 2.978; 95 % CI 1.421–6.243)], and SCCAg greater than 1.5 μg/L [model 1 (p = 0.023; OR 2.431; 95 % CI 1.129–5.235), model 2 (p = 0.024; OR 2.418; 95 % CI 1.125–5.194)] were independently associated with LNM.ConclusionsPelvic lymphadenectomy may be omitted in patients with SCCAg lower than 1.5 μg/L, superficial stromal invasion and without lymphovascular invasion in stage IA2, IB1, IIA1 squamous cell cervical cancer.

show abstract

“…This may partially attribute to why older women in our study more frequently had residual tumor after conization. When it comes to serum SCC antigen levels, we speculate that it may partially be explained by its correlation with tumor burden (25–27). Serum SCC levels have been reported to be associated with clinical stage, tumor size, depth of infiltration, lymphovascular space invasion, and lymph node metastasis in squamous cell carcinoma of the cervix.…”

Section: Discussionmentioning

confidence: 99%

Early stage cervical cancer: role of magnetic resonance imaging after conization in determining residual tumor

et al. 2016

View full text Add to dashboard Cite

show abstract

Squamous cell carcinoma antigen in cervical cancer and beyond

Cited by 15 publications

References 14 publications

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Can pelvic lymphadenectomy be omitted in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer?

Early stage cervical cancer: role of magnetic resonance imaging after conization in determining residual tumor

Contact Info

Product

Resources

About